NCT07059221View on ClinicalTrials.gov

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

July 11, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2028

Conditions
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

SHR-A2102

Administration by intravenous infusion

DRUG

Adebrelimab

Administration by intravenous infusion

DRUG

Cetuximab

Administration by intravenous infusion

Trial Locations (2)

400030

RECRUITING

Chongqing University Cancer Hospital, Chongqing

610041

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT07059221 - A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer | Biotech Hunter | Biotech Hunter